Literature DB >> 18462797

Neurological soft signs as candidate endophenotypes for schizophrenia: a shooting star or a Northern star?

Raymond C K Chan1, Irving I Gottesman.   

Abstract

The crucial role of neurological indicators in schizophrenia has been recognized as among the "target features" that encompass the idea that genetic and non-genetic processes lead to neurointegrative defects later manifested in neurocognitive systems. In addition, aberrant neurological indicators have also been suggested as potential endophenotypes in schizophrenia. In the current paper, we review evidence for the utility of quantifiable neurological soft signs as potential endophenotypes for schizophrenia spectrum disorders. We start by defining endophenotypes and justifying their utility. We highlight the key criteria that must be met for an endophenotype to be useful and assess the extent to which the manifestations of neurological soft signs meet these criteria. Finally, we recommend areas in which additional research should be done to further elucidate the potential use of neurological soft signs for schizophrenia research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462797     DOI: 10.1016/j.neubiorev.2008.01.005

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  53 in total

Review 1.  Annual Research Review: Discovery science strategies in studies of the pathophysiology of child and adolescent psychiatric disorders--promises and limitations.

Authors:  Yihong Zhao; F Xavier Castellanos
Journal:  J Child Psychol Psychiatry       Date:  2016-01-06       Impact factor: 8.982

2.  Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls.

Authors:  Alexandra Miller; Hoa Vo; Liang Huo; Catherine Roca; Peter J Schmidt; David R Rubinow
Journal:  J Psychiatr Res       Date:  2010-02-20       Impact factor: 4.791

Review 3.  Endophenotypes in schizophrenia: a selective review.

Authors:  Allyssa J Allen; Mélina E Griss; Bradley S Folley; Keith A Hawkins; Godfrey D Pearlson
Journal:  Schizophr Res       Date:  2009-02-15       Impact factor: 4.939

4.  The clinical staging and the endophenotype approach as an integrative future perspective for psychiatry.

Authors:  Joachim Klosterkötte
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

Review 5.  Cognition and brain function in schizotypy: a selective review.

Authors:  Ulrich Ettinger; Christine Mohr; Diane C Gooding; Alex S Cohen; Alexander Rapp; Corinna Haenschel; Sohee Park
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

6.  White matter microstructure variations contribute to neurological soft signs in healthy adults.

Authors:  Dusan Hirjak; Philipp A Thomann; Robert C Wolf; Katharina M Kubera; Caspar Goch; Jan Hering; Klaus H Maier-Hein
Journal:  Hum Brain Mapp       Date:  2017-04-21       Impact factor: 5.038

7.  Childhood motor coordination and adult schizophrenia spectrum disorders.

Authors:  Jason Schiffman; Holger J Sorensen; Justin Maeda; Erik L Mortensen; Jeff Victoroff; Kentaro Hayashi; Niels M Michelsen; Morten Ekstrom; Sarnoff Mednick
Journal:  Am J Psychiatry       Date:  2009-07-15       Impact factor: 18.112

8.  Strategies for the study of neuropsychiatric disorders using endophenotypes in developing countries: a potential databank from china.

Authors:  Raymond C K Chan; Irving I Gottesman; Xiaojia Ge; Pak C Sham
Journal:  Front Hum Neurosci       Date:  2010-10-28       Impact factor: 3.169

9.  Convergent approaches for defining functional imaging endophenotypes in schizophrenia.

Authors:  Godfrey D Pearlson; Vince D Calhoun
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

10.  Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design.

Authors:  Raymond C K Chan; Ya Wang; Li Wang; Eric Y H Chen; Theo C Manschreck; Zhan-jiang Li; Xin Yu; Qi-yong Gong
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.